On March 6, 2025, the Connecticut State Legislature introduced Senate Bill 11, a significant legislative measure aimed at addressing the growing concern of prescription drug shortages in the state. The bill establishes a task force dedicated to identifying drugs at risk of shortage and developing strategies to enhance in-state production of these essential medications.

The primary provisions of Senate Bill 11 include the formation of a task force that will report its findings and recommendations annually to relevant legislative committees. This task force will focus on identifying critical prescription drugs that are at risk of shortage and propose methods to mitigate these shortages, including increasing local production capabilities. The bill also expands the existing Strategic Supply Chain Initiative, managed by the Department of Economic and Community Development, to incorporate efforts specifically aimed at preventing drug shortages.

Debate surrounding the bill has highlighted the urgency of addressing prescription drug availability, particularly in light of recent supply chain disruptions exacerbated by global events. Supporters argue that enhancing local production will not only ensure a stable supply of necessary medications but also bolster Connecticut's economy by attracting new business opportunities. However, some critics express concerns about the feasibility of increasing production capacity and the potential costs associated with implementing the proposed strategies.

The implications of Senate Bill 11 are significant, as it seeks to strengthen the state's healthcare infrastructure and ensure that residents have access to vital medications. Experts suggest that if successful, the bill could serve as a model for other states facing similar challenges. The task force's recommendations, due by January 1, 2026, will be closely monitored as stakeholders assess the effectiveness of the initiatives outlined in the legislation.

As the bill progresses through the legislative process, its potential to reshape Connecticut's approach to pharmaceutical supply chain management remains a focal point of discussion among lawmakers, healthcare professionals, and the public.